Olaparib and Bevacizumab in Relapsed Small Cell Lung Cancer Subjects

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

June 11, 2021

Primary Completion Date

October 27, 2023

Study Completion Date

October 27, 2023

Conditions
Lung Cancer
Interventions
DRUG

Olaparib+Bevacizumab to SCLC patients

"Olaparib 300 mg bid per os every 12 hours D1-21 administered in each cycle days. One cycle consists of 21 days.~Bevacizumab 15 mg/kg via IV administered on Day1 of each cycle. One cycle is consisted of 21 days.~The subject's body weight criterion is based on C1D1 (first dose date), and if more than 10% of BW is increased and decreased, the drug dose is changed to that BW."

Trial Locations (1)

Unknown

Samsung Medical Center, Seoul

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

collaborator

Roche Pharma AG

INDUSTRY

lead

Se-Hoon Lee

OTHER